Journal: Biomedicine Hub

Article Title: Study of Baicalin toward COVID-19 Treatment: In silico Target Analysis and in vitro Inhibitory Effects on SARS-CoV-2 Proteases

doi: 10.1159/000519564

Figure Lengend Snippet: The pharmacophore fitting and LigScore results of baicalin and antiviral agents on 3CLpro, PLpro, and RDRP of SARS-CoV-2

Article Snippet: We used pharmacophore models in PharmaDB to determine binding affinities of baicalin plus 3 other positive-control antiviral drugs (remdesivir and lopinavir and ritonavir) to 3CLpro, PLpro, and RDRP of SARS-CoV-2.

Techniques:

Journal: Biomedicine Hub

Article Title: Study of Baicalin toward COVID-19 Treatment: In silico Target Analysis and in vitro Inhibitory Effects on SARS-CoV-2 Proteases

doi: 10.1159/000519564

Figure Lengend Snippet: Molecular docking model of ritonavir and lopinavir binding to 3CLpro. The 3D ligand interaction models at the binding site, between ritonavir (upper left) and lopinavir (upper right) on 3CLpro using Discovery Studio 2021. Lower panel shows statistics of interaction residues between ligands (baicalin, ritonavir, and lopinavir) in the binding site of 3CLpro. 3D, 3-dimensional; 3CLpro, 3-chymotrypsin-like cysteine protease.

Article Snippet: We used pharmacophore models in PharmaDB to determine binding affinities of baicalin plus 3 other positive-control antiviral drugs (remdesivir and lopinavir and ritonavir) to 3CLpro, PLpro, and RDRP of SARS-CoV-2.

Techniques: Binding Assay

Journal: Biomedicine Hub

Article Title: Study of Baicalin toward COVID-19 Treatment: In silico Target Analysis and in vitro Inhibitory Effects on SARS-CoV-2 Proteases

doi: 10.1159/000519564

Figure Lengend Snippet: The potential human targets screening results of baicalin by pharmacophore analysis

Article Snippet: We used pharmacophore models in PharmaDB to determine binding affinities of baicalin plus 3 other positive-control antiviral drugs (remdesivir and lopinavir and ritonavir) to 3CLpro, PLpro, and RDRP of SARS-CoV-2.

Techniques: Derivative Assay, Transferring

Journal: Journal of Inflammation Research

Article Title: Computational Systems Pharmacology, Molecular Docking and Experiments Reveal the Protective Mechanism of Li-Da-Qian Mixture in the Treatment of Glomerulonephritis

doi: 10.2147/JIR.S338055

Figure Lengend Snippet: Docking Results of Three Bioactive Ingredients from Li-Da-Qian Mixture for Glomerulonephritis Targets

Article Snippet: After MCs or mPTCs met 60%–70% confluence, they were pretreated with baicalein (MCE, Cat. No. HY-N0196) at 20μM or luteolin (MCE, Cat. No. HY-N0162) at 5μM for 2h, and then treated with LPS (Sigma, L2280) at 20 μg/mL or human recombinant TGFβ1 (240-B, R&D company) at 10ng/mL for 24 h.

Techniques: Binding Assay

Journal: Journal of Inflammation Research

Article Title: Computational Systems Pharmacology, Molecular Docking and Experiments Reveal the Protective Mechanism of Li-Da-Qian Mixture in the Treatment of Glomerulonephritis

doi: 10.2147/JIR.S338055

Figure Lengend Snippet: Baicalein treatment protected from LPS-induced acute kidney injury. ( A ) Serum biochemical levels in mice (n=5–6) treated with different doses of baicalein after 24h LPS administration. ( B ) The inflammatory factors in the renal cortex of LPS-induced acute kidney injury model with or without different doses of baicalein (n=5–6). ( C ) Representative images of hematoxylin and eosin staining (magnification: ×200, scalebar: 50μm) of kidneys after 24h LPS administration. **p < 0.01, ***p < 0.001 versus the control group, #p < 0.05 versus the LPS group.

Article Snippet: After MCs or mPTCs met 60%–70% confluence, they were pretreated with baicalein (MCE, Cat. No. HY-N0196) at 20μM or luteolin (MCE, Cat. No. HY-N0162) at 5μM for 2h, and then treated with LPS (Sigma, L2280) at 20 μg/mL or human recombinant TGFβ1 (240-B, R&D company) at 10ng/mL for 24 h.

Techniques: Staining, Control

Journal: Journal of Inflammation Research

Article Title: Computational Systems Pharmacology, Molecular Docking and Experiments Reveal the Protective Mechanism of Li-Da-Qian Mixture in the Treatment of Glomerulonephritis

doi: 10.2147/JIR.S338055

Figure Lengend Snippet: Effects of baicalein and luteolin treatment for LPS-induced glomerulonephritis by Western blotting and qPCR. Cells were grown on 6-well or 12-well plates until 60–70% confluence, pretreated with baicalein or luteolin for 2h, and sequentially stimulated with LPS (20μg/mL) for another 24 h. Western blotting results for baicalein therapeutic effect ( A ), densitometric analysis ( B ) and qPCR results for baicalein therapeutic effect ( C and D ). Western blotting results for luteolin therapeutic effect ( E ), densitometric analysis ( F ) and qPCR results for luteolin therapeutic effect ( G and H ). Protein results are shown as mean ± SEM (n = 3) and mRNA results are displayed as mean ± SEM (n=6). *p < 0.05, **p < 0.01, ***p < 0.001 versus the control group, # p < 0.05, ## p < 0.01, ### p < 0.001 versus the LPS group.

Article Snippet: After MCs or mPTCs met 60%–70% confluence, they were pretreated with baicalein (MCE, Cat. No. HY-N0196) at 20μM or luteolin (MCE, Cat. No. HY-N0162) at 5μM for 2h, and then treated with LPS (Sigma, L2280) at 20 μg/mL or human recombinant TGFβ1 (240-B, R&D company) at 10ng/mL for 24 h.

Techniques: Western Blot, Control

Journal: Journal of Inflammation Research

Article Title: Computational Systems Pharmacology, Molecular Docking and Experiments Reveal the Protective Mechanism of Li-Da-Qian Mixture in the Treatment of Glomerulonephritis

doi: 10.2147/JIR.S338055

Figure Lengend Snippet: Effects of baicalein and luteolin treatment for TGFβ1-induced renal fibrosis by Western blotting and qPCR. Cells were grown on 6-well or 12-well plates until 60–70% confluence, pretreated with baicalein or luteolin for 2h, and sequentially stimulated with TGFβ1 (10ng/mL) for another 24 h. Western blotting results for baicalein therapeutic effect ( A ), densitometric analysis ( B ) and qPCR results for baicalein therapeutic effect ( C ). Western blotting results for luteolin therapeutic effect ( D ), densitometric analysis ( E ) and qPCR results for luteolin therapeutic effect ( F ). Protein and mRNA results are displayed as mean ± SEM (n=3). *p < 0.05, **p < 0.01, ***p < 0.001 versus the control group, # p < 0.05, ## p < 0.01, ### p < 0.001 versus the TGFβ1 group.

Article Snippet: After MCs or mPTCs met 60%–70% confluence, they were pretreated with baicalein (MCE, Cat. No. HY-N0196) at 20μM or luteolin (MCE, Cat. No. HY-N0162) at 5μM for 2h, and then treated with LPS (Sigma, L2280) at 20 μg/mL or human recombinant TGFβ1 (240-B, R&D company) at 10ng/mL for 24 h.

Techniques: Western Blot, Control

Journal: Cancer Management and Research

Article Title: 12-lipoxygenase promotes tumor progress by TGF-β1-mediated epithelial to mesenchymal transition and predicts poor prognosis in esophageal squamous cell carcinoma

doi: 10.2147/CMAR.S212478

Figure Lengend Snippet: Expression of 12-LOX was inhibited by Baicalein in a concentration-dependent way in ESCC cells. The left panel showed that the expression levels of 12-LOX in Eca109 cells were gradually inhibited after treated with 20 µM and 40 µM Baicalein, and right panel indicated similar results observed in Kyse150 cells. Abbreviation: ESCC, esophageal squamous cell carcinoma.

Article Snippet: ESCC cells were treated with Baicalein (Selleck, China) or DMSO (Solarbio, China) for 24 hrs with or without pretreated with 100 nM 12(S)-HETE (Cayman Chemical, USA) 4 hrs prior to the inhibitor.

Techniques: Expressing, Concentration Assay

Journal: Cancer Management and Research

Article Title: 12-lipoxygenase promotes tumor progress by TGF-β1-mediated epithelial to mesenchymal transition and predicts poor prognosis in esophageal squamous cell carcinoma

doi: 10.2147/CMAR.S212478

Figure Lengend Snippet: Effects of Baicalein and 12(S)-HETE on the migration and invasion ability in ESCC cells. Representative images of migrated cells ( A, B ) and invaded cells ( C, D ) stained by crystal violet. Left, control cells; second, cells treated by 40 µM Baicalein; third, cells pretreated with 12(S)-HETE before treated by Baicalein (Eca109: A and C; Kyse150: B and D). Analyzed results of the cell migration and invasion assays are shown in a, b, c, d. The number of migrated cells and invaded cells in the Baicalein group was significantly less than those of the control ( P <0.001), and the inhibition was partly relieved when pretreated with 12(S)-HETE. *** P <0.001 vs Control group. Abbreviation: ESCC, esophageal squamous cell carcinoma.

Article Snippet: ESCC cells were treated with Baicalein (Selleck, China) or DMSO (Solarbio, China) for 24 hrs with or without pretreated with 100 nM 12(S)-HETE (Cayman Chemical, USA) 4 hrs prior to the inhibitor.

Techniques: Migration, Staining, Control, Inhibition

Journal: Cancer Management and Research

Article Title: 12-lipoxygenase promotes tumor progress by TGF-β1-mediated epithelial to mesenchymal transition and predicts poor prognosis in esophageal squamous cell carcinoma

doi: 10.2147/CMAR.S212478

Figure Lengend Snippet: Expression of 12-LOX/12(S)-HETE was associated with TGF-β1 and EMT markers in ESCC cells. The left panel showed that the expression levels of TGF-β1, vimentin and N-cadherin in Eca109 cells were inhibited after treated by Baicalein and that of E-cadherin was increased, and the down-regulated level of EMT was partly relieved when pretreated with 12(S)-HETE; right panel indicates similar results observed in Kyse150 cells. Abbreviations: ESCC, esophageal squamous cell carcinoma; EMT, epithelial-mesenchymal transition.

Article Snippet: ESCC cells were treated with Baicalein (Selleck, China) or DMSO (Solarbio, China) for 24 hrs with or without pretreated with 100 nM 12(S)-HETE (Cayman Chemical, USA) 4 hrs prior to the inhibitor.

Techniques: Expressing